Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome

Rheumatol Int. 2012 Jan;32(1):249-51. doi: 10.1007/s00296-009-1322-8. Epub 2009 Dec 18.

Abstract

Hyperimmunoglobulin D and periodic fever syndrome (HIDS) is a rare, hereditary autoinflammatory condition, characterized by recurrent inflammatory episodes. There is no proven treatment for HIDS, but various drugs including, non-steroidal anti-inflammatory drugs, colchicine, steroids, statins and thalidomide have all been tried. Recently, some patients have demonstrated a good clinical response to either etanercept or anakinra. We report a case of a 10-year-old girl who experienced prolonged and severe inflammatory attacks, when she was treated with etanercept, and later with anakinra.

Publication types

  • Case Reports

MeSH terms

  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / therapeutic use
  • Child
  • Etanercept
  • Female
  • Fever / chemically induced*
  • Fever / physiopathology
  • Humans
  • Immunoglobulin G / adverse effects*
  • Immunoglobulin G / therapeutic use*
  • Interleukin 1 Receptor Antagonist Protein / adverse effects*
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*
  • Mevalonate Kinase Deficiency / drug therapy*
  • Mevalonate Kinase Deficiency / physiopathology
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Time Factors
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antirheumatic Agents
  • Immunoglobulin G
  • Interleukin 1 Receptor Antagonist Protein
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Etanercept